



Consultation review – May 2019

Review decision

Published: 10 May 2019

www.nice.org.uk

Proposal to update the existing guidance

NICE planned a review of TA375 in January 2019.

This is the date at which NICE decides whether sufficient new evidence has emerged for the Appraisal Committee to be asked to undertake a review appraisal.

TA375 includes optimised positive recommendations for patients with severe disease only. It concluded that biological disease-modifying antirheumatic drugs (DMARDs) are not a cost-effective use of NHS resources for people with moderate active disease.

Although TA375 included biosimilar infliximab, since its publication, new biosimilars for adalimumab and etanercept have become available and there have been changes in the confidential prices paid by NHS England for all treatments considered in TA375. The availability of cheaper treatments may reduce the committee's preferred ICER to £20,000 to £30,000 per QALY gained for people with moderate active disease.

It is therefore proposed that a partial review of TA375 for people with moderate active disease only should be planned into the appraisal work programme because the price reductions may change the existing, negative recommendations in TA375 for patients with moderate disease.

In order to be completely confident that this is appropriate, we have asked all relevant consultees and commentators, to inform us of any evidence that will help us decide the best way to update this guidance.

[Consultation paper](#)

[Stakeholder list](#)